Immediate and Medium-Term (6 Months) Results of BVS Absorb Biodegradable Coronary Scaffolds Installation in Patients with Chronic Forms of Coronary Artery Disease

Aim of study To evaluate the immediate and medium-term (6 months) results of BVS Absorb biodegradable stents implantation in patients with chronic forms of coronary artery disease, taking into account their location in coronary vessels, morphological nature of the initial lesion of the coronary arteries and technical features of implantation as well.
Material and methods From June 2014 to December 2015, 199 biodegradable stents (Absorb Bioresorbable Vascular Scaffold — BVS; Abbott Vascular, CA, USA) were routinely installed in 114 patients treated at the Interventional Cardioangiology Center of I.M. Sechenov First Moscow State Medical University. The analysis of the obtained results was carried out depending on the type of coronary artery lesion, the length and diameter of the stents, and the details of the angioplasty procedure. To characterize the type of coronary artery lesion, the ACC/AHA classification was used: type A vascular lesion (95 coronary segments); type B vascular disease (68 coronary segments); type C vascular disease (36 coronary segments). The ultimate goal of the study was to study the frequency of thrombosis and in-stent stenosis of stented coronary arteries.
Results The immediate success of scaffold implantation was 98.2%. Complications in the early hospital period were 1.8% (acute stent thrombosis was observed in 2 cases on the first day after implantation). In the medium-term (~6 months), 102 patients (89.5%) with 172 previously placed stents underwent comparison selective coronary angiography. The rest of the patients with stents refused to undergo coronary angiography due to good health and underwent a telephone survey.
The satisfactory result of stenting in the medium-term (6 months) was a completely preserved lumen of the stented area, or with less than 50% stenosis of this place, which comprised 94.3%. The frequency of in-stent stenosis (narrowing of the lumen of the stented area by 50% or more) was 5.7%. In-stent stenosis was detected in groups of patients with type B and C lesions, respectively, in 4% and 1.7%. In the group with type A coronary artery disease, in-stent stenosis was not detected in the medium-term period.
Conclusion The immediate and medium-term results of stenting with the biodegradable BVS Absorb stent were successful in the vast majority of cases (94.3%). Only in 2 cases (1.8%), acute thrombosis of the stent was observed immediately after stenting.

1. Gruentzig A. Transluminal dilatation of coronary-artery stenosis (letter to the editor). Lancet. 1978;1(8058):263. PMID:74678 https://doi.org/10.1016/s0140-6736(78)90500-7.

2. Karpov YuA, Samko AN, Buza VV. Koronarnaya angioplastika i stentirovanie. Moscow: Meditsinskoe informatsionnoe agentstvo Publ.; 2010. (In Russ.).

3. Kuznetsova IE, Tsereteli NV, Sukhorukov OE, Asadov DA. Chreskozhnye koronarnye vmeshatel’stva s ispol’zovaniem lekarstvennykh stentov: proshloe, nastoyashchee i budushchee (obzor dannykh literatury). International Journal of Interventional Cardioangiology. 2013;32:45–50. (In Russ.).

4. Keh YS, Yap J, Yeo KK, Koh TH, Eeckhout E. Clinical Outcomes of Bioresorbable Scaffold in Coronary Artery Disease: A Systematic Literature Review. J Interv Cardiol. 2016;29(1):57–69. PMID:26728234 https://doi.org/10.1111/joic.12260.

5. Omar WA, Kumbhani DJ. The Current Literature on Bioabsorbable Stents: a Review. Curr Atheroscler Rep. 2019;21(12):54. PMID:31768641 https://doi.org/10.1007/s11883-019-0816-4.

6. Giacchi G, Ortega-Paz L, Brugaletta S, Ishida K, Sabaté M. Bioresorbable vascular scaffolds technology: current use and future developments. Med Devices (Auckl). 2016;9:185–198. PMID:27468252; PMCID: PMC4946828 https://doi.org/10.2147/MDER.S90461.

7. Ioseliani DG, Asadov DA, Babunashvili AM. Koronarnoe stentirovanie i stenty. Moscow: GEOTAR-Media Publ.; 2021. (In Russ.)

8. Verdoia M, Kedhi E, Suryapranata H, Galasso G, Dudek D, De Luca G. Poly (l-lactic acid) bioresorbable scaffolds versus metallic drug-eluting stents for the treatment of coronary artery disease: A meta-analysis of 11 randomized trials. Catheter Cardiovasc Interv. 2020;96(4):813–824. PMID:31730255 https://doi.org/10.1002/ccd.28594.

9. Smits PC, Chang CC, Chevalier B, West NEJ, Gori T, Barbato E, et al. Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE-ABSORB randomised clinical trial. EuroIntervention. 2020;16(8):645–653. PMID:32451321. https://doi.org/10.4244/EIJ-D-19-01079.

10. Kraak RP, Tijssen RYG, van Dongen IM, Elias J, Hofma SH, van der Schaaf RJ, et al. Outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents by coronary complexity: a sub-analysis of the AIDA trial. EuroIntervention. 2020;16(11):e904–e912. PMID:31062692 https://doi.org/10.4244/EIJ-D-18-00884.

11. Kereiakes DJ, Ellis SG, Metzger C, Caputo RP, Rizik DG, Teirstein PS, et al. 3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial. J Am Coll Cardiol. 2017;70(23):2852–2862. PMID:29100702 https://doi.org/10.1016/j.jacc.2017.10.010.

12. Stone GW, Ellis SG, Gori T, Metzger DC, Stein B, Erickson M, et al. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet. 2018;392(10157):1530–1540. PMID:30266412. https://doi.org/10.1016/S0140-6736(18)32283-9. Erratum in: Lancet. 2019;394(10205):1230.

13. Kumar A, Gogas BD, Thompson EW, Burnett GM, Molony D, Hosseini H, et al. Bioresorbable vascular scaffolds versus everolimus-eluting stents: a biomechanical analysis of the ABSORB III Imaging substudy. EuroIntervention. 2020;16(12):e989–e996. PMID:32091401 https://doi.org/10.4244/EIJ-D-19-01128.

14. Danzi GB, Bernelli C, Cerrato E. Outcomes of Optimised Implantation Technique with Bioresorbable scaffolds: A Pooled Analysis of ABSORB-IV and COMPARE-ABSORB Trials. Cardiovasc Revasc Med. 2020;21(4):559–561. PMID: 31422012 https://doi.org/10.1016/j.carrev.2019.07.018.

15. Boeder NF, Weissner M, Blachutzik F, Ullrich H, Anadol R, Tröbs M, et al. Incidental Finding of Strut Malapposition Is a Predictor of Late and Very Late Thrombosis in Coronary Bioresorbable Scaffolds. J Clin Med. 2019;8(5):580. PMID:31035602; PMCID: PMC6571797. https://doi.org/10.3390/jcm8050580

16. Ortega-Paz L, Brugaletta S, Sabaté M. Impact of PSP Technique on Clinical Outcomes Following Bioresorbable Scaffolds Implantation. J Clin Med. 2018;7(2):27. PMID:29415486; PMCID: PMC5852443. https://doi.org/10.3390/jcm7020027

17. Ioseliani DG, Asadov DA, Fomenko VV, Azarov AV, Semitko SP. Fiveyear outcomes of implantation of Absorb biodegradable stents using the bifurcation stenting technique: a case report. Cardiovascular Therapy and Prevention. 2021;20(4):2864. (In Russ.) https://doi.org/10.15829/1728-8800-2021-2864